Treatment With Oral Propranolol for Refractory Classic Cutaneous Kaposi Sarcoma

Abstract

but she was not involved in any of the decisions regarding review of the manuscript or its acceptance.

KSHV infection of endothelial precursor cells with lymphatic characteristics as a novel model for translational Kaposi’s sarcoma studies

“…The KSHV-infected ECFCLYs survived as xenografts in mice for at least a month and recapitulated the hallmarks of KSHV infection, which were significantly reduced upon SOX18 inhibition by SM4. Intriguingly, a recent publication reported a 6-month oral propranolol treatment of a patient with classic KS resulting in a substantial decrease in size of KS lesions associated with a reduction in both vascular proliferation and KSHV infection [ 38 ]. Our findings of SOX18 inhibition using the novel K-ECFCLYs in vivo model and the success of propranolol, an FDA-approved drug and a SOX18 inhibitor, in treating classic KS encourage further investigations on the use of specific SOX18 inhibitors as a future KS therapy [ 39 ].…”

“…Deparaffination, rehydration and epitope revealing were done before staining as described in [ 38 ]. Sections were stained with Hematoxylin (#1092530; Merck Millipore) and Eosin Y (#HT110132; Sigma) and for immunofluorescence using anti-rabbit GFP (a gift from Jason Mercer, University of Birmingham, UK) or anti-rat LANA (Abcam) primary antibodies and secondary anti-rabbit Alexa Fluor 488 or anti-rat Alexa Fluor 647 antibodies (#A11034, #21247; Invitrogen).…”

SOX18 Targeting as a Potential, Viable Therapeutic Avenue for Kaposi Sarcoma

“…This concentration of PAs in well-resourced urban and suburban areas is consistent with the American Academy of Dermatology's recommendation that physicians provide on-site supervision to PAs: most dermatologists reside in cities or near universities, with few practicing in rural settings. 2 Only 1.6% of dermatology PAs identify as Black, 1 which is comparable with the US dermatologist workforce, of whom 3% are Black. The number of Black graduates from PA schools has been steadily declining for decades, from 7% in 1996 to 3.2% in 2019.…”

“…To the Editor We read with great interest the recent observation by Salido-Vallejo et al 1 The authors report a finding in which a 6-month oral propranolol treatment of a patient with classic Kaposi sarcoma (KS) was associated with a substantial decrease in the size of KS lesions that was associated with a reduction in vascular proliferation and KS herpesvirus infection. This is encouraging, because despite decades of research, to our knowledge there are no therapeutic options for KS, and mainstay treatments have low efficacy.…”

“…Päivi M. Ojala, PhD Mathias Francoís, PhD In Reply We appreciate the opportunity to respond to the comments of Ojala and Francoís on our article. 1 We acknowledge the excellent work of Gramolelli et al 2 about the role of SOX18 in the pathogenesis of Kaposi sarcoma (KS). The authors describe how this transcription factor is overexpressed in an endothelial KS model system, and it is associated with the maintenance and replenishment of the population of Kaposi sarcoma herpesvirus infected cells.…”